gabapentin has been researched along with Epilepsy, Complex Partial in 18 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Epilepsy, Complex Partial: A disorder characterized by recurrent partial seizures marked by impairment of cognition. During the seizure the individual may experience a wide variety of psychic phenomenon including formed hallucinations, illusions, deja vu, intense emotional feelings, confusion, and spatial disorientation. Focal motor activity, sensory alterations and AUTOMATISM may also occur. Complex partial seizures often originate from foci in one or both temporal lobes. The etiology may be idiopathic (cryptogenic partial complex epilepsy) or occur as a secondary manifestation of a focal cortical lesion (symptomatic partial complex epilepsy). (From Adams et al., Principles of Neurology, 6th ed, pp317-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 7.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 6.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| " The second patient complained of impotence after a rash while taking phenytoin and carbamazepine." | 3.70 | Improved sexual function in three men taking lamotrigine for epilepsy. ( Carwile, ST; Husain, AM; Miller, PP; Radtke, RA, 2000) |
| "Gabapentin (GBP) is a new antiepileptic drug (AED) approved for adjunctive treatment of complex partial seizures with or without seizures secondarily generalization in adults." | 3.69 | Gabapentin associated with aggressive behavior in pediatric patients with seizures. ( Lo, W; Nahata, MC; Tallian, KB; Tsao, CY, 1996) |
| "Gabapentin (GBP) is a non-protein-bound gamma amino acid which is not subjected to metabolic degradation in man." | 2.68 | Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures. ( Ben-Menachem, E; Hamberger, A; Hedner, T; Persson, LI; Söderfelt, B, 1995) |
| "Gabapentin appears to increase human brain GABA levels." | 2.68 | The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. ( Behar, KL; Lamoureux, D; Mattson, RH; Petroff, OA; Rothman, DL, 1996) |
| "Gabapentin was well tolerated by patients in both dosage groups, and no patients exited the study due to adverse events, despite rapid initiation of full dose within 24 hours." | 2.68 | Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89. ( Bergey, GK; Blume, WT; Crockatt, JG; Garofalo, E; LaMoreaux, L; Leiderman, DB; Morrell, MJ; Morris, HH; Penovich, PE; Pierce, M; Rosenfeld, W, 1997) |
| " Results of outcome measures, including time to exit, completion rate, and mean time on monotherapy, showed no significant differences among dosage groups." | 2.68 | Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83. ( Abou-Khalil, B; Beydoun, A; Cantrell, D; Fischer, J; Garofalo, E; Greiner, M; Harden, C; Hayes, A; Labar, DR; Pierce, M; Ramsay, RE; Sackellares, JC; Uthman, BM, 1997) |
| "Gabapentin is an anti-epileptic drug (AED) that was approved in 1993 for the adjunct treatment of complex partial seizures (CPS) with and without generalization." | 2.41 | Gabapentin: a unique anti-epileptic agent. ( Dougherty, JA; Rhoney, DH, 2001) |
| "Gabapentin has been accepted worldwide as a novel antiepileptic drug with a favourable tolerability profile." | 1.30 | Isolated ataxia as an idiosyncratic side-effect under gabapentin. ( Bittermann, HJ; Herrendorf, G; Kurth, C; Steinhoff, BJ, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (72.22) | 18.2507 |
| 2000's | 5 (27.78) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crespo Pérez, L | 1 |
| Moreira Vicente, V | 1 |
| Cano Ruiz, A | 1 |
| Gobernado Serrano, JM | 1 |
| Cobo Ibañez, N | 1 |
| Milicua Salamero, JM | 1 |
| Petroff, OA | 3 |
| Hyder, F | 1 |
| Rothman, DL | 2 |
| Mattson, RH | 3 |
| Wolf, SM | 1 |
| Shinnar, S | 1 |
| Kang, H | 1 |
| Gil, KB | 1 |
| Moshé, SL | 1 |
| Short, C | 1 |
| Cooke, L | 1 |
| Fromm, GH | 1 |
| Ben-Menachem, E | 1 |
| Söderfelt, B | 1 |
| Hamberger, A | 1 |
| Hedner, T | 1 |
| Persson, LI | 1 |
| Behar, KL | 1 |
| Lamoureux, D | 1 |
| Tallian, KB | 1 |
| Nahata, MC | 1 |
| Lo, W | 1 |
| Tsao, CY | 1 |
| Bergey, GK | 1 |
| Morris, HH | 2 |
| Rosenfeld, W | 1 |
| Blume, WT | 1 |
| Penovich, PE | 1 |
| Morrell, MJ | 1 |
| Leiderman, DB | 1 |
| Crockatt, JG | 1 |
| LaMoreaux, L | 1 |
| Garofalo, E | 2 |
| Pierce, M | 2 |
| Beydoun, A | 1 |
| Fischer, J | 1 |
| Labar, DR | 1 |
| Harden, C | 1 |
| Cantrell, D | 1 |
| Uthman, BM | 1 |
| Sackellares, JC | 1 |
| Abou-Khalil, B | 1 |
| Ramsay, RE | 1 |
| Hayes, A | 1 |
| Greiner, M | 1 |
| Pierce, MW | 2 |
| Shokry, A | 1 |
| Steinhoff, BJ | 1 |
| Herrendorf, G | 1 |
| Bittermann, HJ | 1 |
| Kurth, C | 1 |
| Hamer, HM | 1 |
| Dodrill, CB | 1 |
| Arnett, JL | 1 |
| Hayes, AG | 1 |
| Garofalo, EA | 1 |
| Greeley, CA | 1 |
| Greiner, MJ | 1 |
| Maj, R | 1 |
| Fariello, RG | 1 |
| Pevarello, P | 1 |
| Varasi, M | 1 |
| McArthur, RA | 1 |
| Salvati, P | 1 |
| Husain, AM | 1 |
| Carwile, ST | 1 |
| Miller, PP | 1 |
| Radtke, RA | 1 |
| Collins, TL | 1 |
| Dougherty, JA | 1 |
| Rhoney, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
3 reviews available for gabapentin and Epilepsy, Complex Partial
| Article | Year |
|---|---|
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine; | 2009 |
Gabapentin: discussion.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drugs, Inv | 1994 |
Gabapentin: a unique anti-epileptic agent.
Topics: Acetates; Adult; Amines; Anticonvulsants; Child; Cyclohexanecarboxylic Acids; Epilepsy, Complex Part | 2001 |
6 trials available for gabapentin and Epilepsy, Complex Partial
| Article | Year |
|---|---|
Gabapentin toxicity in children manifesting as behavioral changes.
Topics: Acetates; Affect; Aggression; Amines; Anticonvulsants; Behavior; Child; Cyclohexanecarboxylic Acids; | 1995 |
Seizure frequency and CSF parameters in a double-blind placebo controlled trial of gabapentin in patients with intractable complex partial seizures.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Respon | 1995 |
The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Dose-Response | 1996 |
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89.
Topics: Acetates; Adolescent; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Rel | 1997 |
Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 82/83.
Topics: Acetates; Adolescent; Adult; Ambulatory Care; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecar | 1997 |
Cognitive abilities and adjustment with gabapentin: results of a multisite study.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Double-Blind Method; Epilepsy | 1999 |
9 other studies available for gabapentin and Epilepsy, Complex Partial
| Article | Year |
|---|---|
Brain homocarnosine and seizure control of patients taking gabapentin or topiramate.
Topics: Adult; Amines; Anticonvulsants; Brain Chemistry; Carnosine; Cyclohexanecarboxylic Acids; Drug Therap | 2006 |
Hypomania induced by gabapentin.
Topics: Acetates; Amines; Anticonvulsants; Bipolar Disorder; Cyclohexanecarboxylic Acids; Dose-Response Rela | 1995 |
Gabapentin associated with aggressive behavior in pediatric patients with seizures.
Topics: Acetates; Adolescent; Age Factors; Aggression; Amines; Anticonvulsants; Child; Child Behavior Disord | 1996 |
[Trials with gabapentin monotherapy in patients with complex partial or secondary generalized seizures].
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Do | 1997 |
Isolated ataxia as an idiosyncratic side-effect under gabapentin.
Topics: Acetates; Adult; Amines; Anticonvulsants; Cerebellar Ataxia; Cyclohexanecarboxylic Acids; Dose-Respo | 1997 |
Successful treatment with gabapentin in the presence of hypersensitivity syndrome to phenytoin and carbamazepine: a report of three cases.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Drug Hypersens | 1999 |
Anticonvulsant activity of PNU-151774E in the amygdala kindled model of complex partial seizures.
Topics: Acetates; Alanine; Amines; Amygdala; Animals; Anticonvulsants; Behavior, Animal; Benzylamines; Carba | 1999 |
Improved sexual function in three men taking lamotrigine for epilepsy.
Topics: Acetates; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsies, Partial; | 2000 |
A comparison of four new antiepileptic medications.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose | 2000 |